Navigation Links
Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness

Results to be Presented at the North American Menopause Society 19th Annual


EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer of Bionovo, will provide seminal information on the company's second estrogen receptor beta selective drug candidate that will be entering clinical trials shortly. Bionovo's drug candidate, VG101, is designed to treat postmenopausal vaginal dryness, a condition that affects over 40 million women.

The presentation will describe the mechanism of action of the company's selective estrogen receptor (ER) beta drug candidate and explain the safety advantages of this more highly selective estrogen receptor modulator, VG101, when compared to the currently available hormonal therapies for this indication. The presentation will detail the complete analysis of VG101 in both in vivo and in vitro models as well as present the clinical trial design for their upcoming Phase 1/2 study to evaluate the preliminary safety and efficacy of VG101 in a cohort of postmenopausal women. The presentation will include direct comparisons to existing estrogen therapies, showing VG101's superior efficacy at a cellular level.

"Vaginal dryness is a very painful, day to day, quality of life concern for over 50% of menopausal women. The only available FDA-approved treatment for women is estrogen, which has been proven to increase the risks for a number of potentially fatal diseases including breast and uterine cancers, heart disease, stroke and blood clots," said Dr. Tagliaferri. "Independent studies have shown that the major reason postmenopausal women refrain from sexual activity is due to vaginal dryness. Considering the lack of safe treatment options for this indication, and given the data we have developed on this drug candidate, VG101 could be a superior treatment for the millions of women who want to improve both their quality of life as well as sexual functioning."

The North American Menopause Society (NAMS) is the leading nonprofit organization dedicated to promoting the health and quality of life of menopausal women. NAMS has a multidisciplinary membership of over 2,000 leaders in the field of women's health.

About VG101

VG101 is an intravaginal drug designed for the treatment of vaginal atrophy and dryness in menopausal women. VG101 is a novel estrogen receptor beta selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha, which is known to be implicated in both breast and uterine tumor formation. Phase 1/2 clinical testing of VG101, under the directorship of Dr. Deborah Grady, will commence within the next year.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 ... --> adds a 2015 ... 2010 - 2015 with comprehensive analysis ... range of deal types, such as ... alliances. . ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith has ... Healthcare, a global pioneer in wireless monitoring of ... Boston, MA , Mr. Smith will be ... global commercial strategy.  He will also directly oversee ... build clinical evidence for SensiumVitals, the first early ...
(Date:11/30/2015)... , Nov. 30, 2015  The ... norm in U.S. medical imaging is on ... popular accountable care payer-provider contracts are set ... in their wake, alter provider-vendor relationships. The ... will push forward new purchasing frameworks in ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
(Date:11/30/2015)... ... 01, 2015 , ... The National Association of Professional ... its VIP Woman of the Year Circle. She is recognized with this prestigious ... for professional women, boasting 850,000 members and over 200 operating Local Chapters. , ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... Jones as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. Louis Fetal ... MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI ... of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight and above ...
Breaking Medicine News(10 mins):